SCHEMBL214871

SCHEMBL214871

CC(C)=CCC[C@@H](C)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CC[CH]C(C)(C)C1CC3

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.74
CRYAB P02511 3/20 0.74
USP2 O75604 2/20 0.74
ALDH1A1 P00352 2/20 0.74
CYP3A4 P08684 2/20 0.74
ALOX15 P16050 2/20 0.74
LMNA P02545 1/20 0.74
FNTA P49354 1/20 0.70
FNTB P49356 1/20 0.70
PTGES O14684 4/20 0.59
MEN1 O00255 1/20 0.59
PLA2G1B P04054 1/20 0.59
DNMT1 P26358 1/20 0.59
BLM P54132 1/20 0.59
KMT2A Q03164 1/20 0.59
ATG4B Q9Y4P1 1/20 0.59
PREP P48147 1/20 0.57
PIN1 Q13526 1/20 0.57
CRYAA P02489 1/20 0.52
ACHE P22303 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2370125 0.85 MAPT (0.78) MAPTCRYABUSP2ALDH1A1CYP3A4
Lanosterol SCHEMBL19194030 0.85 MAPT (1.00) MAPTCRYABUSP2ALDH1A1CYP3A4
Lanosterol SCHEMBL14536063 0.85 MAPT (1.00) MAPTCRYABUSP2ALDH1A1CYP3A4
SCHEMBL16249832 0.85 MAPT (0.78) MAPTCRYABUSP2ALDH1A1CYP3A4
Lanosterol SCHEMBL1696473 0.85 MAPT (1.00) MAPTCRYABUSP2ALDH1A1CYP3A4
Lanosterol SCHEMBL14360758 0.85 MAPT (1.00) MAPTCRYABUSP2ALDH1A1CYP3A4
Lanosterol SCHEMBL2154745 0.85 MAPT (1.00) MAPTCRYABUSP2ALDH1A1CYP3A4
Lanosterol SCHEMBL145835 0.85 MAPT (1.00) MAPTCRYABUSP2ALDH1A1CYP3A4
Lanosterol SCHEMBL21348006 0.85 MAPT (1.00) MAPTCRYABUSP2ALDH1A1CYP3A4
Lanosterol SCHEMBL145834 0.85 MAPT (1.00) MAPTCRYABUSP2ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118108875-A Hyaluronic acid derivative composition, pharmaceutical composition, and hyaluronic acid derivative-pharmaceutical conjugate composition 旭化成株式会社 2024-05-31 CN claimed
CN-118027246-A Hyaluronic acid derivative, pharmaceutical composition, and hyaluronic acid derivative-pharmaceutical combination 旭化成株式会社 2024-05-14 CN claimed
US-20200032262-A1 NOVEL TECHNIQUE FOR TREATING CANCER USING STRUCTURALLY-REINFORCED S-TUD GENEDESIGN, INC. (JP) 2020-01-30 US claimed
US-9708628-B2 Cationic lipid having improved intracellular kinetics NOF CORPORATION (JP) 2017-07-18 US claimed
WO-2008155141-A2 NOVEL FACULTATIVE CATONIC STEROLS NOVOSOM AG (DE) 2008-12-24 WO claimed
EP-1345632-A2 ABSORBENT ARTICLES WITH NON-AQUEOUS COMPOSITIONS CONTAINING BOTANICALS Kimberly-Clark Worldwide, Inc. (US) 2003-09-24 EP claimed
WO-2002051456-A2 ABSORBENT ARTICLES WITH NON-AQUEOUS COMPOSITIONS CONTAINING BOTANICALS KIMBERLY-CLARK WORLDWIDE, INC. (US) 2002-07-04 WO claimed
US-5759565-A DRUG FOR NASAL ADMINISTRATION NOVARTIS CORPORATION (US) 1998-06-02 US claimed
CN-118108876-A Hyaluronic acid derivative, pharmaceutical composition, and hyaluronic acid derivative-pharmaceutical combination 旭化成株式会社 2024-05-31 CN disclosed
CN-118108877-A Hyaluronic acid derivative composition, pharmaceutical composition, and hyaluronic acid derivative-pharmaceutical conjugate composition 旭化成株式会社 2024-05-31 CN disclosed
CN-118108875-A Hyaluronic acid derivative composition, pharmaceutical composition, and hyaluronic acid derivative-pharmaceutical conjugate composition 旭化成株式会社 2024-05-31 CN disclosed
EP-4368657-A1 PH-RESPONSIVE LIPID DERIVATIVE NOF Corporation (JP) 2024-05-15 EP disclosed
CN-118027246-A Hyaluronic acid derivative, pharmaceutical composition, and hyaluronic acid derivative-pharmaceutical combination 旭化成株式会社 2024-05-14 CN disclosed
US-20240131049-A1 CIRCULAR RNA COMPOSITIONS AND METHODS ORNA THERAPEUTICS, INC. 2024-04-25 US disclosed
US-20020143160-A1 High purity polysaccharide containing hydrophobic group and process for producing it NOF CORPORATION 2002-10-03 US disclosed
EP-1166745-A1 COSMETICS CONTAINING POLYSACCHARIDE-STEROL DERIVATIVES NOF CORPORATION (JP) 2002-01-02 EP disclosed
EP-1113023-A1 METHOD OF FORMING AGGLOMERATES OF POLYSACCHARIDE WITH HYDROPHOBIC GROUPS NOF CORPORATION (JP) 2001-07-04 EP disclosed
WO-2000064407-A1 ABSORBENT TISSUES PROVIDING SKIN BARRIER ENHANCEMENT KIMBERLY-CLARK WORLDWIDE, INC. (US) 2000-11-02 WO disclosed
EP-1026174-A1 HIGH-PURITY POLYSACCHARIDE CONTAINING HYDROPHOBIC GROUPS AND PROCESS FOR PRODUCING THE SAME NOF CORPORATION (JP) 2000-08-09 EP disclosed
EP-0007474-B1 STEROLINHEMIESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Roecar Holdings (Netherlands Antilles) N.V. (AN) 1985-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240131049-A1 CIRCULAR RNA COMPOSITIONS AND METHODS RTCB, HNRNPA1, HNRNPAB MAPT 4190/4885CRYAB 2007/4885USP2 3455/4885
US-20200032262-A1 NOVEL TECHNIQUE FOR TREATING CANCER USING STRUCTURALLY-REINFORCED S-TUD SLIRP, HNRNPDL, KHDRBS1 MAPT 1287/4885CRYAB 2508/4885USP2 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.